ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Annovis Bio Inc

Annovis Bio Inc (ANVS)

2.60
-0.10
(-3.70%)
2.6985
0.0985
(3.79%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.6985
Bid
-
Ask
-
Volume
372,330
2.53 Day's Range 2.84
1.11 52 Week Range 17.88
Market Cap
Previous Close
2.70
Open
2.74
Last Trade
1
@
2.7
Last Trade Time
Financial Volume
$ 990,776
VWAP
2.661
Average Volume (3m)
457,941
Shares Outstanding
19,486,231
Dividend Yield
-
PE Ratio
-2.08
Earnings Per Share (EPS)
-1.26
Revenue
-
Net Profit
-24.59M

About Annovis Bio Inc

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301. Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
-
Annovis Bio Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker ANVS. The last closing price for Annovis Bio was $2.70. Over the last year, Annovis Bio shares have traded in a share price range of $ 1.11 to $ 17.88.

Annovis Bio currently has 19,486,231 shares outstanding. The market capitalization of Annovis Bio is $52.61 million. Annovis Bio has a price to earnings ratio (PE ratio) of -2.08.

ANVS Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2515-8.525423728812.953.07922.572841242.73827385CS
40.668532.93103448282.033.481.9455945562.8304904CS
120.998558.73529411761.73.481.114579412.06744873CS
26-1.7615-39.49551569514.465.61.114757402.74294299CS
52-2.5915-48.9886578455.2917.881.117420418.14613889CS
156-8.3415-75.557065217411.0423.90991.113546918.94404772CS
260-2.3015-46.0351321.1138439922.96217834CS

ANVS - Frequently Asked Questions (FAQ)

What is the current Annovis Bio share price?
The current share price of Annovis Bio is $ 2.6985
How many Annovis Bio shares are in issue?
Annovis Bio has 19,486,231 shares in issue
What is the market cap of Annovis Bio?
The market capitalisation of Annovis Bio is USD 52.61M
What is the 1 year trading range for Annovis Bio share price?
Annovis Bio has traded in the range of $ 1.11 to $ 17.88 during the past year
What is the PE ratio of Annovis Bio?
The price to earnings ratio of Annovis Bio is -2.08
What is the reporting currency for Annovis Bio?
Annovis Bio reports financial results in USD
What is the latest annual profit for Annovis Bio?
The latest annual profit of Annovis Bio is USD -24.59M
What is the registered address of Annovis Bio?
The registered address for Annovis Bio is 1111B S GOVERNORS AVENUE, KENT, DOVER, DELAWARE, 19904
What is the Annovis Bio website address?
The website address for Annovis Bio is www.annovisbio.com
Which industry sector does Annovis Bio operate in?
Annovis Bio operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SSTSystem1 Inc
$ 9.4801
(54.65%)
1.95M
GMSGMS Inc
$ 100.27
(23.77%)
5.81M
CRCLCircle Internet Group Inc
$ 240.795
(20.64%)
92.39M
UAAUnder Armour Inc
$ 7.035
(14.02%)
20.76M
OSCROscar Health Inc
$ 21.235
(13.13%)
70.66M
EVTLVertical Aerospace Ltd
$ 5.21
(-11.54%)
948.28k
VOYGVoyager Technologies Inc
$ 44.93
(-10.16%)
2.37M
NOTEFiscaNote Holdings Inc
$ 0.50245
(-9.68%)
3.02M
NRGVEnergy Vault Holdings Inc
$ 0.80715
(-9.25%)
1.58M
SESSES AI Corporation
$ 0.8401
(-8.87%)
10.59M
BBAIBigBear ai Holdings Inc
$ 3.9974
(0.94%)
167.33M
AMCRAmcor plc
$ 8.97
(-0.88%)
124.08M
FFord Motor Company
$ 10.60
(1.63%)
116.66M
CRCLCircle Internet Group Inc
$ 240.795
(20.64%)
92.39M
OSCROscar Health Inc
$ 21.235
(13.13%)
70.66M

ANVS Discussion

View Posts
ppl_first ppl_first 2 days ago
JUNK should be the ticker for this company. Horrible performance.
👍️0
tredenwater2 tredenwater2 5 days ago
Wait for the final play of this act…..the buyout offer 75% above the 5 yr low.

The dead board is purposefully designed to drive away impatient investors after the hype around the secondaries fades. Nothing the company can say right now can help as trials are ongoing and over promotion is discouraged by gov. agencies.
👍️0
ppl_first ppl_first 2 weeks ago
Dead board. This company needs to start attending investor fairs. They need some interest from institutions.
👍️0
ppl_first ppl_first 2 weeks ago
Dead board. This company needs to start attending investor fairs. They need some interest from institutions.
👍️0
ppl_first ppl_first 2 weeks ago
Companies often schedule investor webcasts when they have positive developments, strategic updates, or milestones to communicate. The presence of the CEO, especially in biotech, usually signals confidence and a controlled narrative. However, it's not a guarantee of good news. Webcasts can also be used to manage expectations, clarify prior results, or preemptively address market concerns.
👍️0
Pedro2004 Pedro2004 2 weeks ago
I was going to sell a couple of days ago when this dropped below $3.00 -- still holding.
Will most likely sell if this goes back to $2.50
👍️0
Pedro2004 Pedro2004 2 weeks ago
Thanks for the info.
👍️0
ppl_first ppl_first 2 weeks ago
Alright I'm changing my view. The price mostly held after the 30% pop earlier this week. I assume that's a good sign. Steady upticks each week from here on would be great! See you at $60
👍️0
ppl_first ppl_first 3 weeks ago
Price rise with no news, huge volume... gotta be either a pump and dump, though I can't find any new articles in the penny stock magazines, or buying by some insider before dilution. Either way we are all sure to get screwed. I took profits today and am out until the dust settles.
👍️0
tredenwater2 tredenwater2 3 weeks ago
The exact same way it closed over $100 with preliminary data. All on hype and manipulation through High Frequency Trading.

The company is nearing a capital raise and big money henchmen never pay top dollar. They always short the stock down, especially low floaters like Anvs, and then get in with their “subscriber” buddies riding the sale of the equity stake up. Wash rinse repeat.

All imho of course
👍️0
ppl_first ppl_first 3 weeks ago
How is the float 19.1M and this is in the dollar range? Seems impossible, right? Also with only 100M in market cap, this doesn't support a successful outlook. Where is the big money at? Sorry, new here, this one is interesting as Phase 3 is underway.
👍️0
makinezmoney makinezmoney 1 month ago
$ANVS: She's been going for a week........ now $1.90

Looking at July 18, 2025 $2.50 Calls are now at $0.16

Possibility this gets to $5/shprice and these calls get to $0.60 if this keeps up


GO $ANVS
👍️0
tredenwater2 tredenwater2 1 month ago
Good luck with your investment. I agree they will run this up as dilution occurs as this stock is very thinly traded and if they want control they will force more secondary’s raising the sharecount.

My money instead is on AVXL. They submitted to the EMA for Alzheimers and we should hear something by Nov-Jan if not earlier.
👍️0
Pedro2004 Pedro2004 1 month ago
I have 2,500 shares as a lottery ticket. I think there's going to be another run in the near future.

.
👍️0
tredenwater2 tredenwater2 2 months ago
Transfer of wealth from the impatient to the patient, just like clockwork. Might be a good entry price.
👍️0
tredenwater2 tredenwater2 2 months ago
Secondary into the market? Great price for the shorts who have been faithful.
👍️0
Pedro2004 Pedro2004 3 months ago
Yes, I agree -- very slow.
And they're dumping shares for financing.
👍️0
Monksdream Monksdream 4 months ago
ANVS, new 52 week low
👍️0
Here Today Here Today 4 months ago
Watch Out FDA!!!! There is a new Sheriff in town and all your CROOKED DEALS with those Big Pharma's of the world trying to STOP and Destroy new Treatments and or cures before they can begin is coming to an end in my opinion!!!!
👍️ 2
Here Today Here Today 4 months ago
I am starting to believe that people have not realized how the confirmation of Robert F. Kennedy Jr truly means for this stock and company.... If anyone was to pay attention to his hearing and some of his pressers of how he specifically mentions Amyloid plaques are a hallmark of Alzheimer's disease and how we need more treatments addressing this issue!!!!

👍️ 1
tedpeele tedpeele 4 months ago
never mind - I see what you meant - phase 3 is starting out slow.
👍️0
tedpeele tedpeele 4 months ago
why do you say 2 people? Their website says this:

The study was completed with 345 patients, of which 90 were identified as having mild AD (MMSE 21-24). These 90 AD patients showed dose-dependent, statistically significant improvements from placebo in the two higher concentrations (15mg, p=0.042; 30mg, p=0.015) and all doses showed significant improvement over baseline (7.5mg, p= 0.013; 15mg p=0.001; 30mg p
👍️ 1
zeusgodmd zeusgodmd 4 months ago
We hit the bottom last 2 days.
👍️0
Pedro2004 Pedro2004 4 months ago
Wow, after all this time...they (just) started phase III. And that's with only 2 people being tested.

Will be Summer until some news comes out.
👍️0
zeusgodmd zeusgodmd 4 months ago
Stock will be over 100$ some day
👍️0
abew4me abew4me 5 months ago
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD.

"The launch of our highly anticipated AD study is a significant milestone in advancing buntanetap toward market approval and addressing the unmet medical need of millions of patients. Our previous trials have delivered compelling results, and we have meticulously designed a comprehensive protocol to evaluate both the symptomatic and potential disease-modifying effects of our drug candidate,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis.

The Phase 3 trial is a randomized, placebo-controlled, double-blind study designed to evaluate the safety and efficacy of a daily dose of buntanetap in patients with early AD. The treatment will last for 18 months and will consist of two parts: a 6-month assessment of symptomatic effects followed by an additional 12-month evaluation of buntanetap’s potential disease-modifying effects. This Phase 3 protocol received FDA approval following positive data from our previous Phase 2/3 trial, which demonstrated significant cognitive improvement in a subgroup of patients with early AD and showed no safety concerns.

The Company has recently completed a public offering of 5,250,000 units consisting of one share of our common stock and one warrant to purchase one share of common stock for gross proceeds of $21 million securing the estimated funding for the initial 6-month portion of the study, while the 12-month phase is expected to be supported by additional capital from the warrant exercises.

"Alzheimer’s steals so much from individuals and their families, but with drugs like buntanetap, we aim to restore quality of life and bring hope to those affected. We are grateful to the community for their continuous support and to everyone who has contributed to making this trial a reality. As we embark on this new chapter, we are optimistic that this study will help redefine the future of Alzheimer’s treatment,” adds Melissa Gaines, SVP of Clinical Operations.

The study’s primary outcomes will include the assessment of cognition using the Alzheimer's Disease Assessment Scale-Cognitive 13 (ADAS-Cog13) subscale and functional ability using the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) scale.

Annovis anticipates enrolling over 750 participants across ~100 sites in the United States. The first two open sites that began recruiting include Conquest Research in Winter Park, FL and Advanced Memory Research Institute of New Jersey in Tom’s River, NJ, each managed by the dedicated teams of Malisa Agard, M.D. and Arun Singh, D.O., respectively. Detailed information about the trial is available at clinicaltrials.gov.

About Buntanetap Buntanetap is a small, orally available molecule that targets neurodegeneration by inhibiting the translation of neurotoxic aggregating proteins and thereby impeding the toxic cascade. This improves axonal transport, synaptic transmission, and reduces neuroinflammation, ultimately restoring the health of nerve cells and brain function. By normalizing these pathways, buntanetap has the potential to reverse neurodegeneration and improve quality of life for patients.

About Annovis Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor AlertsInterested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Forward-Looking StatementsThis press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact Information:Annovis Bio Inc.101 Lindenwood DriveSuite 225Malvern, PA 19355www.annovisbio.com

Investor Contact:Scott McGowanInvestorBrandNetwork (IBN)Phone: 310.299.1717www.annovisbio.com/investors-relationsIR@annovisbio.com


Source: Annovis Bio, Inc.
👍 1
abew4me abew4me 5 months ago
I went ahead and bought 40,153 shares @ $3.47ish today. Now that they've raised $21 Million, I think there is very little downside. The upcoming trial should be exciting.

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025.

In October 2024, the FDA granted clearance for Annovis to proceed with the pivotal Phase 3 AD studies based on its Phase 2/3 data demonstrating cognitive improvement in early-stage AD patients. The original protocol design proposed two separate trials: a 6-month symptomatic study and an 18-month disease-modifying study. Under the revised protocol, these studies are now integrated into a single 6/18-month trial, which will include a 6-month data readout focused on symptomatic effects, followed by an additional 12-month assessment to evaluate the disease-modifying potential of buntanetap.

“This consolidated protocol will accelerate the development timeline while maintaining the scientific rigor necessary to advance buntanetap as a treatment for AD,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. “With this design, we can leverage the 6-month symptomatic data to potentially support a New Drug Application (NDA) filing, all while continuing the same study seamlessly to assess long-term disease-modifying outcomes. We are excited to move forward with this approach, which brings us closer to delivering a novel treatment to patients in need.”

About Annovis Bio

Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.annovisbio.com/email-alerts. Additionally, we invite you to explore our updated investor website, which provides comprehensive access to company news, financial reports, and other key information.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
www.annovisbio.com/investors-relations
IR@annovisbio.com
👍 1
north40000 north40000 5 months ago
Let's hope we're both right, Loof, in our reasons for accumulation. $30+ would be good.

👍️0
Pedro2004 Pedro2004 5 months ago
This was supposed to be a great PR this morning.
👍️0
Pedro2004 Pedro2004 5 months ago
All my hopes in the company has ended.
👍️0
Pedro2004 Pedro2004 5 months ago
This went up 64% premarket, and 20 minutes into trading it's in the red by 8%.
👍️0
Pedro2004 Pedro2004 5 months ago
The company has become a scam enterprise.
👍️0
Pedro2004 Pedro2004 5 months ago
I'll have to agree with you. I watched this hit $8.76 premarket, dumping, then right back down to yesterday's close at $5.35.
👍️0
tredenwater2 tredenwater2 6 months ago
HF’s must be licking their lips readying for another round of funding using every market event to further their profit.
👍️0
Pedro2004 Pedro2004 6 months ago
I bought 2,000 shares of this one...even though it looks like this might drop lower with the selling.
👍️0
tredenwater2 tredenwater2 6 months ago
Wow!

“ Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace”

What did the Annovis CEO “showcase” that would drive the price down?

Is the company needing to raise more money again? If so then the drop makes sense.
👍️0
TekNuLoof TekNuLoof 7 months ago
Long on ANVS. Been holding and accumulating for about a year. I believe this company has a game changing drug for Parkinson’s and Alzheimer’s disease. Analyst target is $30. I believe it can go. Much higher.

Jmo
Loofman
👍️0
TechandBio TechandBio 8 months ago
Starter $7.90

$ANVS
👍️0
Here Today Here Today 9 months ago
Is that Chart of yours showing the nice squeeze play I saw or are my eyes deceiving me?
👍️0
Here Today Here Today 9 months ago
Or is it that it has been shorted to a point and now a reverse is in effect??? What’s your chart say???
👍️0
Here Today Here Today 9 months ago
Hmmmm. Has a deal announcement been leaked?????
👍️0
Monksdream Monksdream 9 months ago
ANVS under $10
👍️0
vegasopc vegasopc 11 months ago
$$$ANVS$$$ Conf on Weds could mean MONSTER WEEK AHEAD! $$$ GLTA
👍️0
Here Today Here Today 11 months ago
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap

MALVERN, Pa.

July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future clinical trials.

In June 2024, Annovis announced the filing of a composition of matter patent for the new crystal form of buntanetap and a provisional patent for the manufacturing process of this new form. The Company conducted comprehensive bridge studies in various solvents and in animals, comparing the old semi-crystalline form with the new crystalline form of buntanetap. Additionally, Annovis developed an innovative large-scale manufacturing process for the new form. This comprehensive data was submitted to the FDA for review.

The FDA has now approved the continuation of buntanetap's development using the new crystal form. This positive response allows Annovis to conduct a comparative study between the old and new forms of buntanetap in a small, single-dose, bioavailability study in humans as part of the transition process.
👍️0
Here Today Here Today 11 months ago
Oh yeah!
👍️0
vegasopc vegasopc 11 months ago
$$$ANVS$$$ Glad I got mine!!! $$$
👍️0
Here Today Here Today 11 months ago
Agreed on the $20+ ANVS share price coming.

But if you want a Cancer Breakthrough treatment, take a look at RNAZ which has an extremely low OS if 6.6 million shares. They constantly get shorted same like ANVS does, but huge difference is the extremely low outstanding share count.

Hopefully we can see a cure for Parkinson’s, Alzheimer’s and cancer in short fashion. Good luck.
👍️0
TechandBio TechandBio 11 months ago
$ANVS look for continuation higher! 20.00+ coming.
Also loading breast cancer cure! $ICCM.
$ANVS
👍️0
G-star G-star 11 months ago
Isn't that the problem with almost every stock nowadays?
If it has to be,ANVS will succeed no matter the amount of shorting.
GLTY
👍️0
Pedro2004 Pedro2004 11 months ago
The shorting is too strong. I'm concerned about getting back in.
👍️0

Your Recent History

Delayed Upgrade Clock